

EMA/506632/2020
EMEA/H/C/005169

Obiltoxaximab SFL (*obiltoxaximab*)

CV]hcl UI]a UV'G: @

CV]hcl UI]a UV'G: @

CV]hcl UI]a UV'G: @

ž

ž

ž

Bacillus anthracis"p

3

CV]hcl UI]a UV'G: @

flCV]hcl UI]a UV'G:

fl CV]hcl UI]a UV'G: @
ema.europa.eu/medicines/human/orphan-designations/eu3182065.

CV]hcl UI]a UV'G: @

&(&\$%

ema.europa.eu/medicines/human/orphan-designations/eu3182065.

CV]hcl UI]a UV'G: @3

Obiltoxax]a UV'G: @

CV]hcl UI]a UV'G: @

\$
CV]hcl UI]a UV'G: @

CV]hcl UI]a UV'G: @

CV]hcl UI]a UV'G: @3

Official address Domenico Scarlattilaan 6 1083 HS Amsterdam The Netherlands

Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us

Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000

An agency of the European Union

ž

CV]hcl UI]a UV'G: @

3

CV]hcl UI]a UV'G: @

fl
G: @

\$ * \$
ž
ž
ž

CV]hcl UI]a UV'G: @3

%)
%\$
€
G: @ž

CV]hcl UI]a UV'G: @fl

łž ž ž

CV]hcl UI]a UV'

CV]hcl UI]a UV'G: @

3

CV]hcl UI]a UV'G: @

p

) \$

CV]hcl UI]a UV'G: @

CV]hcl UI]a UV'G: @

CV]hcl UI]a UV'G: @ž

CV]hcl UI]a UV'G: @3

ž ž

